This Article is no longer available, this page is showing similar articles.

Food, Drugs, Healthcare, Life Sciences

Subscribe

Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.

A "New Era" Of Consumer Medicine? FDA Takes Another Swipe At "Unapproved" Compounded Drugs

For years, the commercial compounding and telehealth industry blossomed, buoyed by exploding consumer interest in GLP-1s and other compounded drugs. But things are changing.

United States Healthcare

SM

Sheppard, Mullin, Richter & Hampton LLP

Understanding The Anti-Kickback Statute

The Anti-Kickback Statute ("AKS") (42 U.S.C § 1320a-7b(b)), is a federal law that prohibits healthcare providers from knowingly and willfully offering or accepting any form of remuneration to induce or reward patient...

United States Healthcare

MS

Miller Shah

Back To The Well: FDA's Draft Guidance On New Clinical Investigation Exclusivity

FDA recently published a new draft Guidance for Industry titled "New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and Answers" (Mar. 2026) (the "Draft Guidance").

United States Healthcare

AV

Axinn Veltrop & Harkrider

AI Is Transforming Life Sciences. The Oversight Structures Are Still Catching Up.

As AI changes drug discovery and patent filing, governance frameworks are being constructed around technology that is not waiting for them...

United States Healthcare

WD

Wiggin & Dana

Targeted Healing Before Birth: Placenta-Derived Stem Cells In Prenatal Repair Of Spinal Defects

United States Healthcare

FL

Foley & Lardner

NDSee You In 2033: FDA's 12‑Digit NDC Is Coming

United States Healthcare

AF

ArentFox Schiff

Are You Tracking The Right NSPM-33 Research Security Program Deadline—or Just The Popular One?

United States Healthcare

B

BakerHostetler

OCR Launches Part 2 Civil Enforcement Program

United States Healthcare

BB

Bass, Berry & Sims

Health-E Law Episode 22: J.P. Morgan Healthcare 2026 And Beyond: Regulation, Technology And The Future Of Health Equity (Podcast)

United States Healthcare

SM

Sheppard, Mullin, Richter & Hampton LLP

When Performance Management Meets Age Bias Claims: Lessons From Chreky V. University Of Pittsburgh Physicians

United States Healthcare

KD

Kelley Drye & Warren LLP

CMS CY 2027 Advance Notice Includes Flat Rate Increase And Modified Methodologies

United States Healthcare

SM

Sheppard, Mullin, Richter & Hampton LLP

8 Things To Know About CMS's Nationwide Moratorium On DMEPOS Medical Supply Companies

United States Healthcare

KM

Katten Muchin Rosenman LLP

FDA Accepts Dr. Reddy's Laboratories' BLA For Abatacept Biosimilar

United States Healthcare

GP

Goodwin Procter LLP

FDA Issues Draft Guidance Clarifying Three-Year New Clinical Investigation Exclusivity

United States Healthcare

AP

Arnold & Porter

See more

Webinars

See More

Recorded on 20 Jan 2026 | 3:00 PM

2026 Canadian In-House Counsel Report: Unparalleled Insights into Canada's In-House Profession from CBA In-House Lawyers

TC

CBA In-House Lawyers

Recorded on 24 Jun 2025 | 3:00 PM

(2nd Session) 2025 Global In-House Counsel Survey Report: Unique Insights into the Global In-House Counsel Profession

IC

In-House Counsel Worldwide

Recorded on 24 Jun 2025 | 9:00 AM

(1st Session) 2025 Global In-House Counsel Survey Report: Unique Insights into the Global In-House Counsel Profession

IC

In-House Counsel Worldwide

Recorded on 30 Apr 2025 | 2:00 PM

Mondaq | 2025 Law Firm Data Landscape Report

mm

Mondaq

Highlighted Content

Plausibility At The EPO – An Update On G2/21

United States Healthcare

D

Dehns

Infringement Of Repurposed Drug Patents And Skinny Labelling – Where Does The Balance Lie In The United States Today?

United States Healthcare

D

Dehns

Infringement Of Repurposed Drug Patents And Skinny Labelling – Where Does The Balance Lie In Europe Today?

United States Healthcare

D

Dehns

How Good Does A Copy Need To Be?

United States Healthcare

D

Dehns

Supplementary Protection Certificates – European Patent Term Extensions

United States Healthcare

D

Dehns

How Much Experimental Data Is Needed For Patent Applications In Europe?

United States Healthcare

D

Dehns

The Silent Treatment: The EPO's Approach To Non-therapeutic Methods Encompassing Therapeutic Effects

United States Healthcare

D

Dehns

Implications Of The Genetic Technology (Precision Breeding) Bill On The Life Science IP Sector

United States Healthcare

D

Dehns

Protection For Plant Varieties In Europe And The UK Post-Brexit

United States Healthcare

D

Dehns

Best Practice For Invention Harvesting

United States Healthcare

D

Dehns

Life Sciences, Biotechnology & Nanotechnology

Understanding The Anti-Kickback Statute

The Anti-Kickback Statute ("AKS") (42 U.S.C § 1320a-7b(b)), is a federal law that prohibits healthcare providers from knowingly and willfully offering or accepting any form of remuneration to induce or reward patient...

United States Healthcare

MS

Miller Shah

Back To The Well: FDA's Draft Guidance On New Clinical Investigation Exclusivity

FDA recently published a new draft Guidance for Industry titled "New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and Answers" (Mar. 2026) (the "Draft Guidance").

United States Healthcare

AV

Axinn Veltrop & Harkrider

AI Is Transforming Life Sciences. The Oversight Structures Are Still Catching Up.

As AI changes drug discovery and patent filing, governance frameworks are being constructed around technology that is not waiting for them...

United States Healthcare

WD

Wiggin & Dana

NDSee You In 2033: FDA's 12‑Digit NDC Is Coming

United States Healthcare

AF

ArentFox Schiff

Are You Tracking The Right NSPM-33 Research Security Program Deadline—or Just The Popular One?

United States Healthcare

B

BakerHostetler

FDA Accepts Dr. Reddy's Laboratories' BLA For Abatacept Biosimilar

United States Healthcare

GP

Goodwin Procter LLP

HHS Asks The Public: How Can Federal Action Help Accelerate AI Use In Clinical Care?

United States Healthcare

SM

Sheppard, Mullin, Richter & Hampton LLP

2025 Year In Review: Life Sciences Licensing & Collaboration Deals

United States Healthcare

GP

Goodwin Procter LLP

New Referral To The Enlarged Board Of Appeal Expected Regarding Claim Interpretation In The Context Of Added Subject Matter

United States IP

JA

J A Kemp LLP

See more

Healthcare

Understanding The Anti-Kickback Statute

The Anti-Kickback Statute ("AKS") (42 U.S.C § 1320a-7b(b)), is a federal law that prohibits healthcare providers from knowingly and willfully offering or accepting any form of remuneration to induce or reward patient...

United States Healthcare

MS

Miller Shah

AI Is Transforming Life Sciences. The Oversight Structures Are Still Catching Up.

As AI changes drug discovery and patent filing, governance frameworks are being constructed around technology that is not waiting for them...

United States Healthcare

WD

Wiggin & Dana

State AG News: Rental Price Fixing, AI Regulation In Healthcare, Student Loans (February 26- March 4, 2026)

Each week, Crowell & Moring's State Attorneys General team highlights significant actions that State AGs have taken.

United States Technology

CM

Crowell & Moring LLP

Targeted Healing Before Birth: Placenta-Derived Stem Cells In Prenatal Repair Of Spinal Defects

United States Healthcare

FL

Foley & Lardner

NDSee You In 2033: FDA's 12‑Digit NDC Is Coming

United States Healthcare

AF

ArentFox Schiff

OCR Launches Part 2 Civil Enforcement Program

United States Healthcare

BB

Bass, Berry & Sims

Health-E Law Episode 22: J.P. Morgan Healthcare 2026 And Beyond: Regulation, Technology And The Future Of Health Equity (Podcast)

United States Healthcare

SM

Sheppard, Mullin, Richter & Hampton LLP

When Performance Management Meets Age Bias Claims: Lessons From Chreky V. University Of Pittsburgh Physicians

United States Healthcare

KD

Kelley Drye & Warren LLP

CMS CY 2027 Advance Notice Includes Flat Rate Increase And Modified Methodologies

United States Healthcare

SM

Sheppard, Mullin, Richter & Hampton LLP

See more

Food and Drugs Law

A "New Era" Of Consumer Medicine? FDA Takes Another Swipe At "Unapproved" Compounded Drugs

For years, the commercial compounding and telehealth industry blossomed, buoyed by exploding consumer interest in GLP-1s and other compounded drugs. But things are changing.

United States Healthcare

SM

Sheppard, Mullin, Richter & Hampton LLP

Understanding The Anti-Kickback Statute

The Anti-Kickback Statute ("AKS") (42 U.S.C § 1320a-7b(b)), is a federal law that prohibits healthcare providers from knowingly and willfully offering or accepting any form of remuneration to induce or reward patient...

United States Healthcare

MS

Miller Shah

Back To The Well: FDA's Draft Guidance On New Clinical Investigation Exclusivity

FDA recently published a new draft Guidance for Industry titled "New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and Answers" (Mar. 2026) (the "Draft Guidance").

United States Healthcare

AV

Axinn Veltrop & Harkrider

Targeted Healing Before Birth: Placenta-Derived Stem Cells In Prenatal Repair Of Spinal Defects

United States Healthcare

FL

Foley & Lardner

NDSee You In 2033: FDA's 12‑Digit NDC Is Coming

United States Healthcare

AF

ArentFox Schiff

Are You Tracking The Right NSPM-33 Research Security Program Deadline—or Just The Popular One?

United States Healthcare

B

BakerHostetler

CMS CY 2027 Advance Notice Includes Flat Rate Increase And Modified Methodologies

United States Healthcare

SM

Sheppard, Mullin, Richter & Hampton LLP

FDA Issues Draft Guidance Clarifying Three-Year New Clinical Investigation Exclusivity

United States Healthcare

AP

Arnold & Porter

OIG Special Advisory Bulletin Addresses Direct-to-Consumer Prescription Drug Sales And Provides A Framework For Compliant Programs

United States Healthcare

WS

Winston & Strawn LLP

See more

Latest Videos

See more

GT Legal Food Talk Episode 30: Navigating Liquor Licensing: Inside The Legal Food & Beverage Landscape (Podcast)

GT

Greenberg Traurig, LLP

Leaders In Law: Life Sciences And Technology Transactions With Jekkie Kim (Video)

W

WilmerHale

Digging Into New York's New Price-Gouging Rules (Video)

BS

Bond, Schoeneck & King PLLC

Pay Transparency + The Power Of Preventive Strategies: Episode 3 — Pivoting Toward Preparation In The Life Sciences (Video)

JL

Jackson Lewis P.C.

Episode 37: Chanda Center For Health: Reimagining Access To And Delivery Of Long-term Disability Care (Podcast)

FL

Foley & Lardner

Upcoming Events

Exploring The Subtleties And Safe Zones Of Off-Label Communications — Part 2

United States Healthcare

FL

Foley & Lardner

Marsh Health Tech Symposium

United States Healthcare

SM

Sheppard, Mullin, Richter & Hampton LLP

New CMS Rural Health Transformation Program: Purpose, Funding Eligibility And Allocation, Healthcare Provider Impact

United States Healthcare

FH

Foley Hoag LLP

AHLA Health Care Transactions Program 2026

United States Healthcare

AV

Axinn Veltrop & Harkrider

Virtual Forty-Third National HIPAA Summit

United States Healthcare

HK

Holland & Knight

Institute On Medicare And Medicaid Payment Issues

United States Healthcare

FL

Foley & Lardner

Medicare Advantage Fraud Enforcement Under A New Administration: Mitigating Risk For Criminal And Civil Actions

United States Healthcare

M

Mintz

Healthy AI Forum

United States Healthcare

SM

Sheppard, Mullin, Richter & Hampton LLP

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More